uplarafenib   Click here for help

GtoPdb Ligand ID: 12882

Synonyms: Compound A [WO2022119905A2]
Compound class: Synthetic organic
Comment: Uplarafenib is the INN for a BRAF inhibitor that was designed as an antineoplastic agent. It is one of the compounds claimed in patent WO2022119905A2 (NeuPharma) [1]. Uplarafenib is likely Henlius/NeuPharma lead BRAF asset HLX208 (RX208), that is designed to target oncogenic BRAFV600E.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 108.81
Molecular weight 494.49
XLogP 1.28
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCS(=O)(=O)NC1=CC(=C(C(=C1F)C(=O)C2=CC=C3C(=C2)N=C(C=N3)N4CCOCC4)F)F
Isomeric SMILES FC1=C(C=C(C(=C1C(=O)C=2C=C3N=C(C=NC3=CC2)N4CCOCC4)F)F)NS(=O)(=O)CCC
InChI InChI=1S/C22H21F3N4O4S/c1-2-9-34(31,32)28-17-11-14(23)20(24)19(21(17)25)22(30)13-3-4-15-16(10-13)27-18(12-26-15)29-5-7-33-8-6-29/h3-4,10-12,28H,2,5-9H2,1H3
InChI Key HAYBWDINAFTFCJ-UHFFFAOYSA-N
Bioactivity Comments
Information provided in WO2022119905A2 suggests that this compound has inhibitor activity across a range of kinases, inlcuding ARAF, BRAF (including mutants), CRAF-1, Fak, FGFR1-4, Jnk1-13, Lek, Lyn, Met, Pim1-3, Pyk2, KDR, Src and Ret with pM-nM potencies [1]. It appears to be most potent against BRAF and BRAF mutants (BRAFV600E, BRAFV600E/T5291).